NasdaqGS:TECH

Stock Analysis Report

Executive Summary

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide The company operates through two segments, Protein Sciences, and Diagnostics and Genomics.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Bio-Techne's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.8%

NasdaqGS:TECH

2.1%

US Life Sciences

1.2%

US Market


1 Year Return

0.6%

NasdaqGS:TECH

9.5%

US Life Sciences

1.7%

US Market

TECH underperformed the Life Sciences industry which returned 9.5% over the past year.

TECH underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

TECHIndustryMarket
7 Day6.8%2.1%1.2%
30 Day4.2%5.6%4.9%
90 Day-3.5%0.4%3.7%
1 Year1.3%0.6%9.7%9.5%3.9%1.7%
3 Year92.1%87.0%81.2%79.8%47.2%37.7%
5 Year126.1%114.2%119.4%109.0%60.0%42.4%

Price Volatility Vs. Market

How volatile is Bio-Techne's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bio-Techne undervalued based on future cash flows and its price relative to the stock market?

79.11x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Bio-Techne's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Bio-Techne's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Bio-Techne is overvalued based on earnings compared to the US Life Sciences industry average.

Bio-Techne is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Bio-Techne is poor value based on expected growth next year.


Price Based on Value of Assets

Bio-Techne is overvalued based on assets compared to the US Life Sciences industry average.


Next Steps

Future Growth

How is Bio-Techne expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

20.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Bio-Techne's revenue is expected to grow by 10% yearly, however this is not considered high growth (20% yearly).

Bio-Techne's earnings are expected to grow significantly at over 20% yearly.

Bio-Techne's revenue growth is expected to exceed the United States of America market average.

Bio-Techne's earnings growth is expected to exceed the United States of America market average.

Bio-Techne's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Bio-Techne is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Bio-Techne performed over the past 5 years?

-0.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Bio-Techne's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

Bio-Techne's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Bio-Techne's 1-year earnings growth is negative, it can't be compared to the US Life Sciences industry average.


Return on Equity

Bio-Techne has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Bio-Techne used its assets less efficiently than the US Life Sciences industry average last year based on Return on Assets.


Return on Capital Employed

Bio-Techne's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Bio-Techne's financial position?


Financial Position Analysis

Bio-Techne is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Bio-Techne's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Bio-Techne's level of debt (44.4%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (1.8% vs 44.4% today).

Debt is well covered by operating cash flow (35.1%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 7.2x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.8x debt.


Next Steps

Dividend

What is Bio-Techne's current dividend yield, its reliability and sustainability?

0.65%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Bio-Techne's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).

Bio-Techne's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).

Bio-Techne is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Bio-Techne is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Bio-Techne's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of Bio-Techne's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Bio-Techne's salary, the management and board of directors tenure and is there insider trading?

5.1yrs

Average management tenure


CEO

Chuck Kummeth (59yo)

6.4yrs

Tenure

US$9,664,874

Compensation

Mr. Charles R. Kummeth, also known as Chuck, has been the Chief Executive Officer and President of Bio-Techne Corporation since April 1, 2013 and served as its Chief Financial Officer since January 2014. M ...


CEO Compensation Analysis

Chuck's remuneration is higher than average for companies of similar size in United States of America.

Chuck's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.1yrs

Average Tenure

58yo

Average Age

The average tenure for the Bio-Techne management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

6.8yrs

Average Tenure

65yo

Average Age

The tenure for the Bio-Techne board of directors is about average.


Insider Trading

More shares have been bought than sold by Bio-Techne individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$37,00011 Sep 19
Charles Kummeth
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares200
Max PriceUS$185.00
BuyUS$95,53009 Aug 19
Robert Baumgartner
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares500
Max PriceUS$191.06

Ownership Breakdown


Management Team

  • Brenda Furlow (61yo)

    Senior VP

    • Tenure: 5.1yrs
    • Compensation: US$1.22m
  • Chuck Kummeth (59yo)

    CEO, President & Director

    • Tenure: 6.4yrs
    • Compensation: US$9.66m
  • Jim Hippel (48yo)

    Senior VP of Finance & CFO

    • Tenure: 5.4yrs
    • Compensation: US$2.45m
  • Dave Eansor (58yo)

    President of Protein Sciences Segment

    • Tenure: 5.2yrs
    • Compensation: US$1.59m
  • Gerry Andros

    Vice President of Sales and Marketing

    • Tenure: 0yrs
  • Luca Cicchetti

    Managing Director

    • Tenure: 3.2yrs
  • Kim Kelderman (52yo)

    President of Diagnostics & Genomics

    • Tenure: 1.4yrs
  • Frank Mortari

    Vice President of Corporate Development

    • Tenure: 0yrs

Board Members

  • Bob Baumgartner (63yo)

    Chairman of the Board

    • Tenure: 6.8yrs
    • Compensation: US$308.39k
  • John Higgins (49yo)

    Independent Director

    • Tenure: 10.3yrs
    • Compensation: US$273.39k
  • Joe Keegan (65yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$227.26k
  • Harold Wiens (73yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$248.39k
  • Randolph Steer (69yo)

    Independent Director

    • Tenure: 29.7yrs
    • Compensation: US$265.89k
  • Roel Nusse (69yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$258.39k
  • Chuck Kummeth (59yo)

    CEO, President & Director

    • Tenure: 6.4yrs
    • Compensation: US$9.66m
  • John Denu

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Sachdev Sidhu

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • David Artis

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Bio-Techne Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Techne Corporation
  • Ticker: TECH
  • Exchange: NasdaqGS
  • Founded: 1976
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.614b
  • Shares outstanding: 37.89m
  • Website: https://www.bio-techne.com

Number of Employees


Location

  • Bio-Techne Corporation
  • 614 McKinley Place NE
  • Minneapolis
  • Minnesota
  • 55413
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TECHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 1989
TE1DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1989

Biography

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide The comp ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/14 23:43
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.